Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
- Conditions
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 90
- Registration Number
- NCT05373680
- Locations
- 🇪🇬
Mansoura University, Mansoura, Dakahlia Governorate, Egypt
🇪🇬Tanta University Teaching Hospitals, Tanta, Gharbia Governorate, Egypt
Canagliflozin in Patients With Acute Decompansted Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 142
- Registration Number
- NCT05364190
- Locations
- 🇪🇬
National heart institute, Giza, Egypt
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT05359432
- Locations
- 🇵🇰
Department of Diabetes and Endocrinology at Sindh Government Hospital New Karachi & Dr. Riasat Medical Center Allah Wala Town, Karachi, Pakistan, Karachi, Sindh, Pakistan
Emp-Activity: Empagliflozin Functional Capacity
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3451
- Registration Number
- NCT05350202
- Locations
- 🇧🇬
Dr. Petrova, Yambol, Bulgaria
🇧🇬Dr. Toneva-Zhelaeva, Yambol, Bulgaria
🇨🇿MUDr. Libor Nechvátal s.r.o., Brno, Czechia
Cognitive Protective Effect of Newer Antidiabetic Drugs
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-10-17
- Target Recruit Count
- 324
- Registration Number
- NCT05313529
- Locations
- 🇨🇳
Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
🇨🇳Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
🇨🇳Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT05282121
- Locations
- 🇺🇸
Floridian Clinical Research-Miami Lakes-68368, Miami Lakes, Florida, United States
🇳🇱Amsterdam UMC, location VUMC, Amsterdam, Netherlands
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 807
- Registration Number
- NCT05254002
- Locations
- 🇺🇸
Healor Primary Care / CCT Research, Las Vegas, Nevada, United States
🇺🇸Santa Rosa Medical Centers of Nevada / CCT Research, Las Vegas, Nevada, United States
🇺🇸Circuit Clinical/Crystal Run, Middletown, New York, United States
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 15
- Registration Number
- NCT05233163
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 42
- Registration Number
- NCT05232071
- Locations
- 🇺🇸
Birmingham Digestive Health Research, Homewood, Alabama, United States
🇺🇸Institute for Liver Health dba Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Cure Clinical Research, LLC, Fountain Valley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.